Elevated levels of lipoprotein(a) [Lp(a) ) are associated with an increased risk of coronary artery disease, but the mechanism(s) by which Lp(a) potentiates atherogenesis is incompletely understood. The recent determination of the cDNA sequence of apo(a), however, has provided unique insight into the structure of Lp(a) and its potential mechanistic relevance for atherothrombosis. Apo(a) demonstrates a remarkable homology to human plasminogen, containing multiple kringle or lysine-dependent fibrin binding domains. In this application, we outline a proposal to investigate the functional consequences of Lp(a) binding to adhesive and matrix proteins on the cellular and extracellular fates of Lp(a). The objectives of this proposal are: 1) to examine the binding of Lp(a) to fibrin(ogen); in particular, to characterize the domains of Lp(a)/apo(a) and of fibrin(ogen) responsible for this binding interaction, to compare the fibrinogen binding properties of the various apo(a) isoforms and cloned kringle 4-like domains, and to assess the role of Lp(a)/apo(a) glycosylation in fibrin(ogen) binding; 2) to investigate the functional consequences of Lp(a) binding to fibrinogen on fibrin polymerization and platelet aggregation; 3) to examine the binding of Lp(a) to collagen and elastin, its modulation by fibrin(ogen), and the importance of Lp(a) interactions with matrix proteins in the accumulation of Lp(a) in the vessel wall; and 4) to investigate the interaction of Lp(a) and fibrin(ogen) with the classic LDL receptor, scavenger receptor, and MAC-1 receptor on monocytes/ macrophages. The experiments outlined in this proposal should provide new insight into the molecular and cellular mechanisms by which thrombotic and atherogenic factors interact. Understanding these mechanisms may provide new information useful in the prevention and treatment of atherosclerotic disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL002768-04
Application #
2210528
Study Section
Research Training Review Committee (RTR)
Project Start
1992-07-01
Project End
1997-06-30
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Rogers, C; Edelman, E R; Simon, D I (1998) A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A 95:10134-9
Simon, D I; Xu, H; Ortlepp, S et al. (1997) 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17:528-35
Wei, Y; Lukashev, M; Simon, D I et al. (1996) Regulation of integrin function by the urokinase receptor. Science 273:1551-5
Simon, D I; Rao, N K; Xu, H et al. (1996) Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88:3185-94
Simon, D I; Mullins, M E; Jia, L et al. (1996) Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Proc Natl Acad Sci U S A 93:4736-41
Simon, D I; Xu, H; Vaughan, D E (1995) Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes. Biochim Biophys Acta 1268:143-51
Simon, D I; Stamler, J S; Loh, E et al. (1995) Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 26:339-42
Suh, T T; Holmback, K; Jensen, N J et al. (1995) Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 9:2020-33